Nazli Okumus

Nov 27, 2024 | radcliffecardiology.com | Sanjiv Shah |Ashley Park |Andrew Coats |Nazli Okumus

Video Published: Views: 22 Likes: 0 Average (ratings) AHA Conference 2024 - Primary safety and efficacy results from ENDEAVOR investigating the effect of myeloperoxidase inhibition with mitiperstat (AstraZeneca) on symptoms and exercise capacity in patients with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF).

Mar 29, 2023 | docwirenews.com | Nazli Okumus

The 2023 sessions of Technology and Heart Failure Therapeutics (THT2023) took place on March 20-22nd, 2023 in Boston with great enthusiasm in technologies that are in the pipeline and amazing discussions about ongoing trials that will shape the future of our clinical practice. One of the most striking sessions was “Unloading in AMI: Changing the paradigm from DTB to DTU” presented by Dr. Navin Kapur.